BCBS of Massachusetts member communications, 2025 New Hampshire Medicaid dropped GLP-1 obesity coverage effective January 1, 2026 affecting Harvard Pilgrim NH Medicaid enrollees
Multi-country, multi-center long-term cardiovascular outcome trials (CVOTs) confirmed that GLP-1RAs decrease cardiovascular mortality and provide cardiovascular benefits to reduce the incidence of MI or non-fatal stroke [3]
[DOI] [PMC free article] [PubMed] [Google Scholar] 18.KUMFU S, SIRI-ANGKUL N, CHATTIPAKORN SC, et al
Fr Menschen mit fleischarmer Ernhrung, bei sportlicher Aktivitt, im Alter oder bei erhhtem Energiebedarf
Havel JJ, Chowell D, Chan TA
The Precision Peptide Genetic Test ($99 add-on) identifies how your body responds to GLP-1 pathways and related peptide mechanisms, which can inform whether GLP-1 therapy was right for you and whether resuming it postpartum aligns with your genetic profile